Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(08)61649-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing renal transporter immunodetection: consequences of freeze-thaw during sample preparation.
Am J Physiol Renal Physiol
October 2024
Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, California, United States.
Renal transporters (cotransporters, channels, and claudins) mediate homeostasis of fluids and electrolytes and are targets of hormonal and therapeutic regulators. Assessing renal transporter abundance with antibody probes by immunoblotting is an essential tool for mechanistic studies. Although journals require authors to demonstrate antibody specificity, there are no consensus guidelines for kidney sample preparation leading to lab-to-lab variability in immunoblot results.
View Article and Find Full Text PDFAprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study.
J Cardiothorac Surg
July 2024
Department of Cardiothoracic Surgery, Castle Hill Hospital, Hull University Teaching Hospitals Trust, Cottingham, UK.
Background: Aprotinin, a serine protease inhibitor, has been used variably in cardiac surgery amidst ongoing debates about its safety following several previous studies. This study assesses the outcomes of aprotinin in high-risk isolated Coronary Artery Bypass Graft (iCABG) patients.
Methods: The study retrospectively analysed a cohort of 1026 iCABG patients, including 51 patients who underwent aprotinin treatment.
Lack of efficacy of aprotinin over tranexamic acid in type A aortic dissection repair.
Transfusion
May 2024
Department of Anaesthesia and Intensive Care Medicine, Royal Papworth Hospital, Cambridge, UK.
Background: The role of aprotinin in modern cardiac surgery is not well defined. While licensed for use in isolated coronary artery bypass grafting it is more commonly used for cases deemed to be at an increased risk of bleeding. The relative efficacy, and safety profile, of aprotinin as compared to other antifibrinolytics in these high-risk cases is uncertain.
View Article and Find Full Text PDFConsensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: Antifibrinolytics.
Hematol Transfus Cell Ther
April 2024
Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM UNIFESP), São Paulo, SP, Brazil.
The use of strategies to reduce blood loss and transfusions is essential in the treatment of surgical patients, including in complex cardiac surgeries and those that use cardiopulmonary bypass. Antifibrinolytics, such as epsilon-aminocaproic acid (EACA) and tranexamic acid (TXA), are widely used in these procedures, as well as in other types of surgeries. These medicines are included in the World Health Organization (WHO) list of 'essential medicines'.
View Article and Find Full Text PDFSGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study.
Kidney Blood Press Res
April 2024
Division of Endocrinology, Diabetology and Nephrology, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany.
Introduction: SGLT2 inhibitors are used to reduce the risk of progression of chronic kidney disease (CKD). In patients with type 2 diabetes, they have been found to reduce extracellular volume. Given the high prevalence of extracellular volume expansion and overhydration (OH) in CKD, we investigated whether SGLT2 inhibitors might correct these disturbances in CKD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!